ECASS health economic feasibility study. Report. ScHARR HEDS Discussion Papers by [email protected] | Oct 30, 2023
Cost-effectiveness of pembrolizumab for first-line treatment in patients with persistent, recurrent, or metastatic cervical cancer in the United States by [email protected] | Oct 30, 2023
Health care resource utilization (HCRU) and costs in patients with biliary tract cancer (BTC) treated with systemic therapy in the United States (US) by [email protected] | Oct 20, 2023
The Impact of the Patient Access Schemes on the Access of Innovative oncology Medicines in Asia-Pacific region: A targeted review by [email protected] | Oct 20, 2023
The power of one: examining the impact of single arm trials on oncology drug approvals by NICE and CADTH by [email protected] | Oct 19, 2023
